Clinical trials: SCHIZOPHRENIA 1 (Disorder), open to volunteers
Schizophrenia / Schizoaffective Disorder, First Episode Psychosis (FEP)
French Minds Cohort: a French Longitudinal and Multimodal Cohort of Patients With Major Mood Disorders, Psychotic Disorders, Autism Spectrum Disorders, and Healthy Controls
The goal of this study is to learn whether people living with severe psychiatric disorders can be grouped into more homogeneous subgroups, across usual diagnostic categories, based on two key dimensions: social withdrawal and…
- Conditions
- Schizophrenia / Schizoaffective Disorder, First Episode Psychosis (FEP), Bipolar Disorder (BD), Major Depressive Disorder (MDD
- Trial name
- FRENCH-MINDS (NCT07881016)
- Testing
- 3T Brain MRI, Biological Sampling, Clinical, Cognitive and Digital Assessments
- Where
- 17 sites in France
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Fondation FondaMental
Schizophrenia, Autism-Related Irritability
A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
The purpose of this study is to evaluate the long-term safety and tolerability of Xanomeline and Trospium Chloride for the treatment of psychiatric disorders in children and adolescents
- Trial name
- NCT07424404
- Testing
- KarXT, KarX-EC
- Where
- 104 sites in United States, Australia and 9 more
- Volunteers
- 400 people
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Prodromal Schizophrenia
Evaluation of Step-Based Care for Individuals at Clinical High Risk for Psychosis
The Ohio State University Early Psychosis Intervention Center is implementing a specialized clinical program to serve individuals who meet clinical high risk criteria for a psychosis.
- Trial name
- NCT03970005
- Testing
- Step-Based Care Model
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Ohio State University
Schizophrenia, Bipolar I Disorder
Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
To evaluate the safety and tolerability of iloperidone in adolescent patients with schizophrenia or bipolar I disorder for up to 52 weeks of treatment.
- Trial name
- NCT05648591
- Testing
- Iloperidone
- Where
- 11 sites in United States
- Volunteers
- 100 people
- Sponsor
- Vanda Pharmaceuticals
Schizophrenia, Bipolar Disorder
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
This is a multicenter, global, 26-week, open-label study to assess the safety and tolerability of lumateperone in pediatric patients with schizophrenia, bipolar disorder or autism spectrum disorder.
- Conditions
- Schizophrenia, Bipolar Disorder, Autism Spectrum Disorder
- Trial name
- NCT06229210
- Testing
- Lumateperone
- Where
- 65 sites in United States, Colombia and 1 more
- Volunteers
- 300 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Schizophrenia Spectrum Disorders (SSD)
Developing Biomarker-Supported Schizophrenia Spectrum Disorder (SSD) Prevention
The purpose of this study is to compare the effect of a brief family-based psychosocial intervention that addresses modifiable SSD risk factors on persistent and distressing psychotic-like experiences in children and young adults…
- Trial name
- NCT07743645
- Testing
- Psychosocial intervention group
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center, Houston
Delusional Disorder, Brief Psychotic Disorder
FEEL-GOOD: A Multicenter Trial of a Mindfulness-Based Group Therapy in Young Adults With Early Psychosis
FEEL-GOOD is a prospective multi-site single-blinded randomized controlled trial in young inpatients with acute early psychosis. Participants are randomized 1:1 to FEEL-GOOD plus treatment as usual (TAU) or TAU alone.
- Conditions
- Delusional Disorder, Brief Psychotic Disorder, Schizophreniform Disorder, Schizophrenia / Schizoaffective Disorder
- Trial name
- FEEL-GOOD (NCT07645443)
- Testing
- FEEL GOOD, Treatment as Usual (TAU)
- Where
- 8 sites in Germany
- Volunteers
- 252 people
- Sponsor
- Stephanie Mehl
Early Psychosis, Psychosis
State Representation in Early Psychosis 2
This observational study will examine behavioral and electroencephalography measures related to state representation in individuals with early psychosis and healthy control participants.
- Conditions
- Early Psychosis, Psychosis, Schizophrenia, Bipolar Disorder With Psychosis
- Trial name
- STEP2 (NCT07834203)
- Where
- 2 sites in United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Psychotic Disorders, Cannabis Use Disorder
Investigating the Neural Correlates of Cognitive Function in Psychosis Patients and Non-Psychiatric Controls With Cannabis Use
Cognitive impairment is well established in people with psychosis and is associated with cannabis use. The current study will investigate the neurobiological basis of cognitive change associated with 28-days of cannabis…
- Conditions
- Psychotic Disorders, Cannabis Use Disorder, Cannabis Dependence, Cannabis Use
- Trial name
- NCT05445180
- Testing
- Contingency management
- Where
- Canada
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- Douglas Mental Health University Institute
Schizophrenia / Schizoaffective Disorder, Schizophrenia and Disorders With Psychotic Feature
Building a Computational Model of Auditory Hallucinations
Some people hear voices or sounds that other people cannot hear; these are called auditory hallucinations. The study aims to understand what is happening in the brain when this occurs and will use brain scans to learn more.
- Conditions
- Schizophrenia / Schizoaffective Disorder, Schizophrenia and Disorders With Psychotic Feature, Psychosis, SCHIZOPHRENIA 1 (Disorder)
- Trial name
- CLARITY WP1 (NCT07820553)
- Volunteers
- 146 people, healthy volunteers welcome
- Sponsor
- King's College London
SCHIZOPHRENIA 1 (Disorder)
Multi-target TMS for Schizophrenia Negative Symptoms
This randomized controlled trial (RCT) is the first to evaluate the efficacy and safety of a multi-target TMS protocol targeting the right orbitofrontal cortex (R-OFC), left dorsolateral prefrontal cortex (L-DLPFC), and left…
- Trial name
- NCT07559084
- Testing
- repetitive transcranial magnetic stimulation (rTMS)
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Shanghai Mental Health Center
Bipolar I Disorder, Schizophrenia
Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects
To evaluate the long-term safety and tolerability of OLZ/SAM in pediatric subjects with schizophrenia or Bipolar I disorder
- Trial name
- NCT04987229
- Testing
- OLZ/SAM
- Where
- 35 sites in United States, Argentina and 3 more
- Volunteers
- 236 people
- Sponsor
- Alkermes, Inc.
Schizophrenia, Bipolar I Disorder
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs olanzapine
- Trial name
- NCT05303064
- Testing
- OLZ/SAM, Olanzapine
- Where
- 47 sites in United States, Argentina and 3 more
- Volunteers
- 220 people
- Sponsor
- Alkermes, Inc.
Schizophrenia, Schizo-Affective Disorder
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
This is a study of the efficacy and safety of BXCL501 in children and adolescents with acute agitation and either bipolar disorder or schizophrenia.
- Conditions
- Schizophrenia, Schizo-Affective Disorder, Schizophreniform; Schizophrenic, Bipolar Disorder I
- Trial name
- NCT05025605
- Testing
- BXCL501 80 Micrograms, BXCL501 120 Micrograms, BXCL501 60 Micrograms
- Where
- 5 sites in United States
- Volunteers
- 140 people
- Sponsor
- BioXcel Therapeutics Inc
Schizophrenia, Schizophrenia Spectrum and Other Psychotic Disorders
Immunoinflammatory State Detection and Multimodal Brain Imaging and Electrophysiologic Changes in Schizophrenia
Schizophrenia is a severe mental illness that seriously affects the health and functioning of patients. Previous studies have found immunoinflammatory abnormalities in the blood, cerebrospinal fluid, central nervous system, and…
- Conditions
- Schizophrenia, Schizophrenia Spectrum and Other Psychotic Disorders, Mental Disorders
- Trial name
- SZIM (NCT06673966)
- Testing
- Regular follow-up assessments without intervention., Cross-sectional assessment
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Central South University
Schizophrenia Disorder, Schizophreniform Disorder
MicroRNAs as Biomarkers in First Episode Schizophrenia
This study investigates whether tiny molecules called microRNAs (miRNAs), found in special brain-derived "packages" (neural-derived extracellular vesicles, or NDEs) that travel from the brain into the blood, can serve as helpful…
- Conditions
- Schizophrenia Disorder, Schizophreniform Disorder, Schizoaffective Disorder, Psychosis Not Otherwise Specified (NOS)
- Trial name
- MIRFEST (NCT07703670)
- Testing
- Plasma NDE miRNA Sequencing, Whole Genome Sequencing
- Where
- United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Northwell Health
Psychosis, Schizophrenia Spectrum Disorders
A Case Series of Culturally-adapted CBTp for Black People in the UK
The goal of this case series study is to learn if culturally-adapted cognitive-behavioural therapy is practical, acceptable and safe among Black Sub-Saharan African and Caribbean people experiencing psychosis.
- Trial name
- NCT07252206
- Testing
- Culturally-adapted cognitive-behavioural therapy
- Where
- United Kingdom
- Volunteers
- 6 people
- Sponsor
- University of Manchester
Schizophrenia Prodromal, Schizophrenia, Childhood
Patientheque in Patients With a Psychosis
Establishment of a patient library for patients who have had a first psychotic episode and who have an "at risk" status for psychotic disorder (GRD, APS, BLIPS group) or a psychosis threshold during CAARMS administration.
- Conditions
- Schizophrenia Prodromal, Schizophrenia, Childhood, Schizophrenia
- Trial name
- LONGIPEP (NCT05340348)
- Testing
- Blood samples (36 mL) + fecal samples + hair sample
- Where
- France
- Volunteers
- 250 people
- Sponsor
- University Hospital, Brest
Schizophrenia Disorder
Mechanisms of Sulforaphane Supplementation in Alleviating Negative Symptoms and Cognitive Impairment in Schizophrenia
The goal of this randomized, double-blind, placebo-controlled clinical trial with an open-label extension is to evaluate whether sulforaphane can improve negative symptoms and cognitive impairment, and to explore its underlying…
- Trial name
- NCT07652866
- Testing
- Sulforaphane
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Second Xiangya Hospital of Central South University
First-episode Psychosis
Biomarkers Predictive of Thymic Evolution and Therapeutic Response at 2 Years in Patients With a First Psychotic Episode
Psychosis is a severe, common, and disabling psychological disorder. An epidemiological study conducted in England reported an incidence of 34 new cases per 100,000 person-years, with a peak between 16 and 19 years of age.
- Trial name
- PEPAMARKER (NCT05384392)
- Testing
- Recorded interview, Clinical scales, Blood sample
- Where
- 5 sites in France
- Volunteers
- 217 people
- Sponsor
- University Hospital, Brest